pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

ADARx Pharmaceuticals Inc

founded 2019 · 125 employees · San Diego, CA, USupdated 5mo ago

ADARx Pharmaceuticals is a clinical-stage biotechnology company developing next-generation RNA-targeted therapeutics, including siRNA, antisense, and proprietary RNA editing (EditR) platforms. Its pipeline spans genetic, cardiometabolic, complement-mediated, and central nervous system diseases, with lead programs ADX-324 (hereditary angioedema) and ADX-038 in clinical development.

Website ↗LinkedIn ↗
community read0 votes
pipeline
1
marketed
0
phase 3
1
catalysts ytd
0
approvals ytd
0
recalls ytd
0

Pipeline(1)

pipeline depth1 products
Phase 3: 1
1Phase 3
Phase 3
onvuzosiran sodium
Hereditary Angioedema (HAE) (C1 Esterase Inhibitor [C1-IN…

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

nothing in the last 90 days
view all catalysts →
🐶 Hiring Signal
No open roles indexed yet — view ADARx Pharmaceuticals Inc jobs →

News

  • 2026 Q3 Job Market Report: Job opportunities, layoffs show YOY improvement
    During Q3, there was a 31% year-over-year increase in job postings live on BioSpace. The number of employees affected by layoffs dropped 90%.
    biospace · 4d ago
  • This week in charts: a big year for RNAi developers
    The latest installment in BioPharma Dive’s data visualization series features a look at the emerging popularity of RNAi developers, and the funding that came with it.
    biopharma_dive · 24d ago
  • Biotech notches 31 IPOs already this year, with 4 more joining queue
    The sector’s IPO tally has surpassed each of the past four years, with four October debuts adding momentum—but activity still remains well below the COVID-19 boom that saw nearly 100 public debuts…
    biospace · 25d ago
  • Alnylam bulls and bears fight it out after business-shaking guidance cut
    While Alnylam’s recent reduced revenue guidance spooked investors, analysts remain broadly bullish on the biotech’s commercial prospects.
    biospace · 27d ago
  • City’s IPO soars to $200M, with proceeds supporting thromboembolic disease pipeline
    City Therapeutics will join a slew of biotechs that have entered the public markets this year, with a $200 million raise that landed above expectations.
    biospace · 1mo ago
  • City goes public with $200M IPO, while Frazier Life Sciences takes biotech-focused SPAC to Nasdaq
    City Therapeutics has gone public with an upsized $200 million IPO, on the same day that Frazier Life Sciences listed its second biotech-focused shell company.
    fiercebiotech · 1mo ago
  • OrbiMed’s largest-ever Asian fund contributes to $3B war chest
    OrbiMed has raised $3 billion to place a fresh round of bets on biotechs and life sciences companies in the U.S., Europe and Asia.
    fiercebiotech · 1mo ago
  • TRexBio, Retension raise $161.7M in IPOs; City, Iambic set proposed offering terms
    TRexBio and Retension Pharmaceuticals are set to debut Friday, bringing this year’s biotech IPO count to 29 as the sector’s rebound continues. City Therapeutics and Iambic Therapeutics hope to push…
    biospace · 1mo ago
  • TCGX launches $600M fund to bankroll Asian biotechs
    Investment firm TCGX is expanding in Asia, raising $600 million to funnel into biotechs emerging from a burgeoning drug discovery hotspot.
    fiercebiotech · 1mo ago
  • TRex Bio stomps toward $111M IPO, as Retension and Lycia also gear up to go public
    Eli Lilly-backed TRex Bio is aiming for a $111.3 million IPO, while hypertension-focused Retension Pharmaceuticals hopes for a more modest $33.8 million and protein degradation biotech Lycia Therap…
    fiercebiotech · 1mo ago
view all news mentions →
identifiers
country
US
source
globaldata
top tags
Immunology1
mentioned in
10news items
entity-linker matched

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?